Study of the Effects of Overfeeding on Glucocorticoids in Lean and Obese Subjects (Gluco-Food)

March 22, 2022 updated by: Eleonora Seelig

The Acute Response of Glucocorticoids Upon Food Intake

Investigators suggest that in lean subjects cortisol increases in response to overfeeding and that this increase is blunted in obese subjects. A group of 18 male healthy lean subjects and another group of 18 male healthy obese subjects will undergo a high-calorie meal test. Prior to the meal intake, an indirect calorimetry, bioelectrical impedance, heart rate variability, a fasting blood sample and a perceived stress questionnaire will be assessed. After intake of the study meal, blood tests will be performed in order to measure the secretion of cortisol, glucose and lipid metabolism and inflammatory markers. Indirect calorimetry will be assessed again 60 and 180 minutes after the meal intake.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Obesity is one of the most serious health problems in the 21st century. High energy food and a sedentary lifestyle are driving the current obesity pandemic. These factors activate the hypothalamic-pituitary-adrenal (HPA) axis, the key regulatory pathway of energy homeostasis. Activation of the HPA-axis leads to secretion of glucocorticoids from the adrenal glands, which control energy homeostasis by mobilizing and redistributing energy substrates.

Animal models of obesity have shown that glucocorticoids play a key role in the development of the metabolic syndrome. However, studies in humans yielded conflicting results. These studies have a major limitation in common. They do not consider glucocorticoid rhythmicity but rather investigate a snapshot of glucocorticoid secretion. Rhythmicity, however, is crucial because already minor glucocorticoid phase disturbances cause disease and could contribute to obesity.

Interestingly, excessive food intake may increase cortisol levels in healthy subjects . The consequence of this food-induced cortisol peak is not understood, but it may be key to restoring energy homeostasis after a meal. Whether the food-induced cortisol peak in obese subjects is disturbed is not known

With this study, investigators aim to better understand the role played by glucocorticoids in the origin of overweight and obesity. Researchers will investigate, in lean and obese subjects, whether the pulsatile release of cortisol increases after intake of a high-calorie meal. 36 subjects will take part in the study: a group of 18 male lean subjects and a second group of 18 male obese patients.

Study Type

Observational

Enrollment (Actual)

36

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Basel-Stadt
      • Basel, Basel-Stadt, Switzerland, 4031
        • University Hospital Basel

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 36 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Sampling Method

Non-Probability Sample

Study Population

Community sample. The obese group will be both a community and a clinical sample.

Description

Inclusion Criteria:

  • Body mass index (BMI) >18,5 and <25 kg/m2
  • BMI >30 kg/m2

Exclusion Criteria:

  • Any clinically significant concomitant diseases in lean subjects
  • Any clinically significant concomitant diseases in obese subjects apart from features of the metabolic syndrome (dyslipidemia, arterial hypertension and insulin resistance)
  • Lactose intolerance
  • Severe food allergy
  • Regular alcohol consumption (>30 g/d)
  • Regular fitness training (>4 hours/week)
  • Previous enrolment in a clinical trial within the last 3 months
  • Inability or contradictions to undergo the investigated intervention
  • Inability to follow the procedures of the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Lean subjects
24 hours before the study visit, participants will be asked to refrain from alcohol and strenuous exercise. Patients will be asked to remain fasted 10 hours before the study visit takes place. On the day of the study visit, patients will be admitted to the hospital and, after intake of the study meal, blood samples will be taken.
Intake of a high-calorie meal (2500-3000 calories) within 15 minutes.
Obese subjects
24 hours before the study visit, participants will be asked to refrain from alcohol and strenuous exercise. Patients will be asked to remain fasted 10 hours before the study visit takes place. On the day of the study visit, patients will be admitted to the hospital and, after intake of the study meal, blood samples will be taken.
Intake of a high-calorie meal (2500-3000 calories) within 15 minutes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in pulsatile secretion of cortisol in response to a high-calorie meal (nmol/l)
Time Frame: 195 minutes
Blood test
195 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Thyroid hormones (nmol/l)
Time Frame: 195 minutes
Blood test
195 minutes
Growth Hormone (mIU/l)
Time Frame: 195 minutes
Blood test
195 minutes
Catecholamines (pg/ml)
Time Frame: 195 minutes
Blood test
195 minutes
Adrenocorticotropic Hormone (ACTH) (pg/ml)
Time Frame: 195 minutes
Blood test
195 minutes
Glucagon-like-peptide-1 (GLP-1) (pg/ml)
Time Frame: 195 minutes
Blood test
195 minutes
Gastric inhibitory polypeptide (GIP) (pg/ml)
Time Frame: 195 minutes
Blood test
195 minutes
Peptide YY (PYY) (pg/ml)
Time Frame: 195 minutes
Blood test
195 minutes
Glucose (mmol/l)
Time Frame: 195 minutes
Blood test
195 minutes
Insulin (mIU/l)
Time Frame: 195 minutes
Blood test
195 minutes
C-Peptide (pmol/l)
Time Frame: 195 minutes
Blood test
195 minutes
Total cholesterol (mmol/l)
Time Frame: 195 minutes
Blood test
195 minutes
Low density lipoprotein (LDL)-cholesterol (mmol/l)
Time Frame: 195 minutes
Blood test
195 minutes
High density lipoprotein (HDL)-cholesterol (mmol/l)
Time Frame: 195 minutes
Blood test
195 minutes
Triglycerides (mmol/l)
Time Frame: 195 minutes
Blood test
195 minutes
Growth differentiation factor 15 (GDF15) (ng/l)
Time Frame: 195 minutes
Blood test
195 minutes
High-sensitive c-reactive Protein (hsCRP) (mg/l)
Time Frame: 195 minutes
Blood test
195 minutes
Interleukin-6 (IL-6) (pg/ml)
Time Frame: 195 minutes
Blood test
195 minutes
Interleukin-8 (IL-8) (pg/ml)
Time Frame: 195 minutes
Blood test
195 minutes
Interleukin-1 receptor Antagonist (IL-1Ra) (pg/ml)
Time Frame: 195 minutes
Blood test
195 minutes
Heart rate (bpm)
Time Frame: 5 minutes
Heart rate variability analysis
5 minutes
Blood pressure: diastolic and systolic blood pressure (mmHg)
Time Frame: 1 minute
Standard blood pressure monitor
1 minute
Weight: kilogram body weight (kg)
Time Frame: 1 minute
Standard scale
1 minute
Energy expenditure: basal metabolic rate
Time Frame: 200 minutes
Indirect calorimetry
200 minutes
Substrate utilisation: respiratory quotient
Time Frame: 200 minutes
Indirect calorimetry
200 minutes
Fat and lean mass (kg)
Time Frame: 20 minutes
Body impedance analysis
20 minutes
Total body water (l)
Time Frame: 20 minutes
Body impedance analysis
20 minutes
Appetite: visual analogue scale rating
Time Frame: 3 hours
Visual analogue scale
3 hours
Stress: perceived stress Levels (0-56)
Time Frame: 5 minutes
Perceived stress questionnaire
5 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Eleonora Seelig, MD, University Hospital, Basel, Switzerland

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 14, 2020

Primary Completion (Actual)

February 20, 2021

Study Completion (Actual)

February 20, 2021

Study Registration Dates

First Submitted

March 30, 2020

First Submitted That Met QC Criteria

July 17, 2020

First Posted (Actual)

July 22, 2020

Study Record Updates

Last Update Posted (Actual)

March 23, 2022

Last Update Submitted That Met QC Criteria

March 22, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 202000384

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Overweight and Obesity

Clinical Trials on High-calorie meal

Subscribe